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To the Editor: 
 
We read with interest “NS5A resistance-associated substitutions in patients with genotype 1 
hepatitis C virus: Prevalence and effect on treatment outcome” by Zeuzem et al. in the Journal 
of Hepatology, which indicated lower SVR rates for Gt1a and Gt1b strains carrying multiple 
resistance-associated substitutions (RASs) in NS5A [1]. Their study is very comprehensive 
but, as the authors note, it is largely restricted to HCV subtypes Gt1a and Gt1b, and does not 
represent subtypes from large geographical regions, including Africa. Indeed, current 
guidelines for treatment with direct-acting antivirals (DAAs) [2] are based on trial data for a 
limited selection of HCV genotypes, typically found in high-income countries. However, HCV is 
highly variable with natural polymorphisms at sites of DAA resistance. Our analysis of patients 
originating from low- and middle-income countries (LMICs), recruited into the NHS England 
Early Access Programme (EAP), has identified HCV subtypes, which contain naturally-occurring 
single and double RAS in NS5A that are associated with apparent poor response to approved 
DAAs. 
Previously, we described clinical outcomes from the EAP cohort, which provided IFN-free, DAA 
therapy to >800 HCV-infected patients with decompensated liver disease [3, 4]; all patients 
received sofosbuvir±ribavirin (SOF±RBV) combined with either ledipasvir (LDV) or daclatasvir 
(DCV). Among the Gt1-infected group, 28 patients did not achieve a SVR. From next 
generation sequence (NGS) analysis, 3 of these patients, designated as Gt1- or Gt1a-infected 
by the clinical sites, were infected with Gt1l. All 3 patients originated from Nigeria. The patients 
were retreated with DAAs for a further 24 weeks but again relapsed after therapy. In two Gt1l- 
infected patients (P1 and P3) where pre- and post-treatment samples were available, there 
were no sequence changes in either NS5A or NS5B. By contrast, NS5A RASs emerged in Gt1a- 
infected patients between pre- and post-treatment. For the 3rd Gt1l-infected patient, NGS data 
was only available at pre-treatment. 
Typically, RAS in NS5A are located at positions 24, 28, 30, 31 and 93 as well as residue 58 
(for Gt1a) [1]. However, these positions are polymorphic among HCV genotypes/subtypes. 
The Gt1l sequences in patients P1 and P3 between residues 28-31 were identical (MPRM; Table 
1). Thus, at pre-treatment, both patients contained two documented RAS (Q30R+L31M). The 
  
3rd gt1l-infected patient, P2, had one RAS (L31M). In a recent report, introducing Q30R+L31M 
into a Gt1a replicon confers high in vitro resistance for LDV and DCV (>23,400 and >4,452 
increased EC50 values, respectively); for Velpatasvir, there is a 198-fold rise in EC50 for these 
substitutions [5]. In the context of Gt1a, L31M also increases EC50 values for these DAAs but 
to a lesser extent compared to Q30R+L31M. 
In the EAP cohort, there were also one non-responder and 3 responder-relapsers in the Gt4- 
infected group. From NGS analysis, the non-responder (P4) and one of the three responder- 
relapsers were infected with Gt4r (P5; Table 1); both patients originated from Somalia. The 
remaining responder-relapsers were Gt4d-infected. Similar to Gt1l-infected patients P1 and 
P3, no amino acid alterations were detected in NS5A between pre- and post-treatment for the 
Gt4r non-responder. The sequence between NS5A residues 28-32 in this patient was identical 
to that for patients P1 and P3 and thus contained a Q30R+L31M RAS doublet. However, a 
T282 RAS in NS5B, which is associated with SOF resistance [6], emerged in 100% of 
sequences at 1 week post-therapy (Figure 1). T282 remained dominant at week 5 post- 
treatment but at 49 weeks, T282 was not detected and all sequences encoded S282. A similar 
pattern of emergence and loss of T282 after failed SOF treatment has been reported in a Gt2b- 
infected patient [7]. The GT4r responder-relapser (P5) had a single NS5A RAS at pre- 
treatment (Q30R) and a further Y93H RAS emerged upon relapse. No amino acid changes 
were observed in NS5B. 
From the limited Gt1l sequences available (n=3), both double (Q30R+L31M) and single RAS 
(L31M) are present in published strains [8]. Combined with our data, NS5A position 30 is 
apparently polymorphic in Gt1l and thereby generates strains with double and single RAS, 
which could increase NS5A DAA resistance. As with Gt1l, there is a paucity of Gt4r sequence 
data. However, in a recently reported Gt4 cohort (n=44), Gt4r was detected in three subjects, 
two of whom did not achieve SVR [9]. The non-SVR Gt4r subjects had baseline RAS 
(M28M/V+Q30R+L31M), which remained the dominant sequences post-treatment. Moreover, 
a S282T mutation in NS5B emerged at post-treatment for one Gt4r patient. These data 
complement our findings and, given that the SOF-resistant S282T variant has emerged in 2/4 
  
Gt4r-infected patients who did not achieve SVR, this substitution may arise with higher 
frequency in rare subtypes such as Gt4r. 
We conclude that certain Gt1l and Gt4r strains contain naturally occurring polymorphisms, 
which could contribute to resistance to NS5A inhibitors in patients with advanced liver disease. 
Since decompensated cirrhosis can lead to reduced response to DAAs [10], it is unclear 
whether extended duration of initial therapy might be advantageous in such patients nor 
whether patients with less liver damage would respond differently. Nevertheless, with the 
growing availability of DAAs, it is important that recommendations and guidance reflect the 
global situation to effectively control HCV infection. Since many DAA combinations for pan- 
genotypic HCV therapy include NS5A inhibitors, robust evidence is critical to evaluate their 
effectiveness against the global diversity of HCV subtypes and further trials may be needed in 
such cohorts to evaluate alternative regimens, perhaps including emerging protease inhibitor 
combinations. The absence of data in exotic HCV strains and the presence of variants 
associated with reduced treatment response pose a potential barrier to HCV eradication. 
Further studies investigating DAA efficacy in these and other strains found in LMICs in cirrhotic 
and non-cirrhotic patients are required. 
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Table 1. Outcomes of DAA treatment/retreatment and sequences at sites of NS5A 
RAS before and after treatment. 
 
 Position of NS5A RAS  
HCV Gt 
Subjects/ 
Reference 
DAA Rx 
Rx Outcome 
(1) 
Rx Outcome 
(2) 
Timepoint 28 29 30 31 32 58 93 
Gt1a Gt1a Ref     M P Q L P H Y 
Gt1b Gt1b Ref     L P R L P P Y 
 
 
 
 
Gt1l 
 
P1 
SOF/LDV/ 
RBV 
 
Resp-Rel 
 
Resp-Rel 
Pre-Rx 
Post-Rx 
M 
M 
P 
P 
R 
R 
M 
M 
P 
P 
P 
P 
Y 
Y 
 
P2 
 
SOF/DCV 
 
Resp-Rel 
 
Resp-Rel 
Pre-Rx 
Post-Rx 
M P Q M 
NA 
P P Y 
 
P3 
SOF/LDV/ 
RBV 
 
Resp-Rel 
 
Resp-Rel 
Pre-Rx 
Post-Rx 
M 
M 
P 
P 
R 
R 
M 
M 
P 
P 
P 
P 
Y 
Y 
Gt4a Gt4a ref     V P L M P P Y 
 
 
 
Gt4r 
 
P4 
 
SOF/LDV 
 
Non-Resp 
Not 
re-treated 
Pre-Rx 
Post-Rx 
M 
M 
P 
P 
R 
R 
M 
M 
P 
P 
P 
P 
Y 
Y 
 
P5 
SOF/LDV/ 
RBV 
 
Resp-Rel 
Not 
re-treated 
Pre-Rx 
Post-Rx 
M 
M 
P 
P 
R 
R 
L 
L 
P 
P 
P 
P 
Y 
H 
NA – sequence not available; Rx outcome (1) and (2) – initial (1) and retreatment (2) 
outcomes. 
  
FIGURE LEGEND 
 
Figure 1. Emergence and loss of RAS S282T in NS5B after therapy in patient P4. Boxes show 
the percentage reads of S282 and T282 from NGS data at pre- and post-treatment. 
 
 
